Adamis Pharmaceuticals reported -7569130 in EBITDA for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Adma Biologics ADMA:US $ -13.22M 1.62M
Brainstorm Cell Therapeutics BCLI:US $ -5.4M 0.74M
Cara Therapeutics CARA:US $ -27848000 5.61M
Cerulean Pharma CERU:US $ -8.4M 1.14M
GlaxoSmithKline GSK:LN 3120M 1062M
Glaxosmithkline GSK:US $ 3120M 1062M
Merk MRK:US $ 6179M 492M
Pfizer PFE:US $ 11182M 4046M